Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

Summary

• On March 5, 2025, Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock at a weighted average price of $10.98 per share.
• The shares were sold in multiple transactions with prices ranging from $10.63 to $11.23.
• On March 6, 2025, Mr. Ma sold another 2,000 shares of common stock at a weighted average price of $10.8 per share.
• These shares were also sold in multiple transactions, with prices ranging from $10.63 to $11.17.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Mr. Ma directly owns no shares, but his spouse indirectly owns 2,843,260 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an insider under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. The use of 10b5-1 trading plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates